☆ 4.7 Meeting Abstract

Phase 2 Study of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-Hodgkin Lymphomas

BLOOD (2021)

Journal

BLOOD

Volume 138, Issue -, Pages -

Publisher

AMER SOC HEMATOLOGY

DOI: 10.1182/blood-2021-151824

Keywords

-

Categories

Hematology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Review Oncology

EBV-Driven Lymphoproliferative Disorders and Lymphomas of the Gastrointestinal Tract: A Spectrum of Entities with a Common Denominator (Part 3)

Magda Zanelli, Francesca Sanguedolce, Andrea Palicelli, Maurizio Zizzo, Giovanni Martino, Cecilia Caprera, Valentina Fragliasso, Alessandra Soriano, Fabrizio Gozzi, Luca Cimino, Francesco Masia, Marina Moretti, Moira Foroni, Loredana De Marco, David Pellegrini, Hendrik De Raeve, Stefano Ricci, Ione Tamagnini, Alessandro Tafuni, Alberto Cavazza, Francesco Merli, Stefano A. Pileri, Stefano Ascani

Summary: The Epstein-Barr virus (EBV) is a common virus infecting the majority of individuals early in life, but only a minority develop EBV-related diseases under conditions of immunosuppression. EBV-driven lymphoid proliferations can originate from B-cells or T/NK-cells, with behaviors ranging from indolent to aggressive, posing challenges for diagnosis and treatment.

CANCERS (2021)

Add to Collection

Article Oncology

B2M mutation paves the way for immune tolerance in pathogenesis of Epstein-Barr virus positive diffuse large B-cell lymphomas

Miaoxia He, Bin Liu, Gusheng Tang, Lijuan Jiao, Xuefei Liu, Shuyi Yin, Tao Wang, Jie Chen, Lei Gao, Xiong Ni, Libin Wang, Lili Xu, Jianmin Yang

Summary: This study investigated the genetic pathogenesis and tumor microenvironment of EBV positive DLBCL in patients without immunodeficiency. The results showed that B2M mutations were significantly increased in these cases and were related to poor patient outcomes. B2M mutations disrupt the expression and functions of HLA, leading to decreased T lymphocyte infiltration in tumor tissues, thus reducing the recognition and elimination of EBV+ tumor cells by the host immune system.

JOURNAL OF CANCER (2022)

Add to Collection

Article Immunology

Prospective evaluation of blood Epstein-Barr virus DNA load and antibody profile in HIV-related non-Hodgkin lymphomas

Julien Lupo, Raphaele Germi, Remi Lancar, Michele Algarte-Genin, Houria Hendel-Chavez, Yassine Taoufik, Nicolas Mounier, Marialuisa Partisani, Fabrice Bonnet, Marie-Caroline Meyohas, Bruno Marchou, Anastasiia Filippova, Sophie Prevot, Dominique Costagliola, Patrice Morand, Caroline Besson

Summary: In the modern cART era, the EBV DNA load in whole blood and plasma at NHL diagnosis does not serve as prognostic markers for HIV-NHL patients.

AIDS (2021)

Add to Collection

Review Medicine, General & Internal

Comparative Study on Epstein-Barr Virus-Positive Mucocutaneous Ulcer and Methotrexate-Associated Lymphoproliferative Disorders Developed in the Oral Mucosa: A Case Series of 10 Patients and Literature Review

Kyoichi Obata, Tatsuo Okui, Sawako Ono, Koki Umemori, Shoji Ryumon, Kisho Ono, Mayumi Yao, Norie Yoshioka, Soichiro Ibaragi, Akira Sasaki

Summary: MTX-LPD or EBV-MCU are diseases related to the use of MTX, mainly associated with EBV infection. A retrospective study found that the oral mucosa is the most common site of onset, and all cases achieved remission. The most common risk factor for developing EBV-MCU is the use of immunosuppressive drugs.

DIAGNOSTICS (2021)

Add to Collection

Article Oncology

EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort

Prashasti Agrawal, Kevin A. A. David, Zhengming Chen, Suchitra Sundaram, Seo-Hyun Kim, Ryan Vaca, Yong Lin, Samuel Singer, Mary-Kate Malecek, Jordan Carter, Adam Zayac, Myung Sun Kim, Nishitha Reddy, Douglas Ney, Alma Habib, Christopher Strouse, Jerome Graber, Veronika Bachanova, Sidra Salman, Jean A. A. Vendiola, Nasheed Hossain, Mazie Tsang, Ajay Major, Maher K. K. Gandhi, Colm Keane, David A. A. Bond, Matthew Folstad, Julie Chang, Angel Mier-Hicks, Pallawi Torka, Priya Rajakumar, Parameswaran Venugopal, Stephanie Berg, Michael Glantz, Samuel A. A. Goldlust, Rahul Matnani, Pallavi Kumar, Thomas A. A. Ollila, Johnny Cai, Stephen E. E. Spurgeon, Alex G. G. Sieg, Joseph Cleveland, Narendranath Epperla, Reem Karmali, Seema Naik, Sonali M. M. Smith, James L. L. Rubenstein, Brad S. S. Kahl, Amy Chadburn, Andrew M. M. Evens, Peter Martin

Summary: The objective of this multicenter retrospective study was to examine the incidence, patient characteristics, pathology, and outcomes associated with Epstein-Barr virus (EBV)-related CNS lymphoma (CNSL) in older patients. The study found that 11.7% of CNSL patients aged ≥ 60 had EBV + tumors, mainly solid organ transplant-related post-transplant lymphoproliferative disorders (PTLD). EBV positive tumors were associated with younger age, solid organ transplant or autoimmune disease, and immunosuppressive treatment. Furthermore, EBV + PTLD had a shorter median overall survival compared to EBV + non-PTLD and EBV-negative patients.

LEUKEMIA & LYMPHOMA (2023)

Add to Collection

Article Virology

Comparison of Elecsys and Liaison immunoassays to determine Epstein-Barr virus serological status using further diagnostic approaches to clarify discrepant results

Julien Lupo, Mansour Tsougaev, Stephane Blachier, Guillaume Chovelon, Aurelie Truffot, Corentin Leroy, Joris Giai, Olivier Epaulard, Raphaele Germi, Patrice Morand

Summary: This study compared the performance of two immunoassays for detecting serological markers of EBV infection. The results showed a high agreement between the two methods, but differences were found in sensitivity and detection rates for early primary infection and past infection.

JOURNAL OF MEDICAL VIROLOGY (2023)

Add to Collection

Article Virology

Spatial Dispersal of Epstein-Barr Virus in South America Reveals an African American Variant in Brazilian Lymphomas

Paula Alves, Marcella Larrate, Aruana Garcia-Costa, Paulo Rohan, Bianca Ervatti Gama, Eliana Abdelhay, Edson Delatorre, Rocio Hassan

Summary: In this study, the genetic diversity of Epstein-Barr virus (EBV) in Brazil was characterized. Four main EBV clades were identified, with the Raji/Argentine and Mediterranean clades being the most prevalent in South America. The Raji/Argentine clade showed associations with certain polymorphisms and high haplotype diversity.

VIRUSES-BASEL (2022)

Add to Collection

Article Medicine, Research & Experimental

High plasma EBV-DNA load and positive EBER status associated with viral recurrence and persistent infection in early treatment of lymphoma

Meichun Zeng, Qingjun Jia, Jingjing Chen, Liming Xu, Li Xie, Qinglin Cheng, Qingchun Li, Ming Xiao, Zijian Fang

Summary: The relationship between plasma EBV-DNA load (PEDL) and Epstein-Barr virus (EBV)-encoded small RNA (EBER) during the early treatment of lymphoma is not well-established. This study found that although EBER affects the levels of PEDL, there is poor concordance between EBER and qualitative analysis of PEDL (qPEDL).

CLINICAL AND EXPERIMENTAL MEDICINE (2023)

Add to Collection

Article Oncology

Epstein-Barr virus recruits PDL1-positive cells at the microenvironment in pediatric Hodgkin lymphoma

O. Jimenez, S. Colli, M. Garcia Lombardi, M. V. Preciado, E. De Matteo, P. Chabay

Summary: The presence of EBV does not influence PD1 and PDL1 expression in pediatric cHL, but in EBV-related cases, a higher number of PDL1+ cells were detected in the microenvironment.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)

Add to Collection

Review Medicine, General & Internal

Management of Epstein-Barr Virus Infection and Post-Transplant Lymphoproliferative Disorder in Pediatric Liver Transplantation

Tatsuya Okamoto, Hideaki Okajima, Elena Yukie Uebayashi, Eri Ogawa, Yosuke Yamada, Katsutsugu Umeda, Hidefumi Hiramatsu, Etsurou Hatano

Summary: With the advancement of immunosuppressive strategies, liver transplantation outcomes have improved significantly in children. However, Epstein-Barr virus infection and post-transplant lymphoproliferative diseases (PTLD), such as malignant lymphoma, remain serious complications that contribute to morbidity and mortality. Recently, early diagnosis through quantitative PCR and PET-CT testing, as well as treatment with rituximab, have shown promising results in achieving long-term remission. However, determining the optimal immunosuppression protocol after PTLD remission and finding treatments for refractory PTLD (e.g., PTL-NOS) are still areas of focus.

JOURNAL OF CLINICAL MEDICINE (2022)

Add to Collection

Review Oncology

Natural Killer Cells in Post-Transplant Lymphoproliferative Disorders

Cecilia Nakid-Cordero, Marine Baron, Amelie Guihot, Vincent Vieillard

Summary: Post-transplant lymphoproliferative disorders (PTLDs) are life-threatening complications after solid organ or hematopoietic stem cell transplants, commonly associated with EBV infection and immunosuppressive therapy. While most PTLD cases are B cell-originated, rare cases involve T cell or NK cell origin. The impaired anti-viral and anti-tumoral immunosurveillance due to long-term immunosuppression is believed to contribute to PTLD pathogenesis, with T cell impairment being critical in EBV-linked complications post-transplantation, while the role of NK cells remains less understood and may vary between EBV-positive and EBV-negative PTLDs.

CANCERS (2021)

Add to Collection

Review Oncology

Impact of Tumour Epstein-Barr Virus Status on Clinical Outcome in Patients with Classical Hodgkin Lymphoma (cHL): A Review of the Literature and Analysis of a Clinical Trial Cohort of Children with cHL

Mandi Nohtani, Katerina Vrzalikova, Maha Ibrahim, Judith E. Powell, Eanna Fennell, Susan Morgan, Richard Grundy, Keith McCarthy, Sarah Dewberry, Jan Bouchal, Katerina Bouchalova, Pamela Kearns, Paul G. Murray

Summary: The Epstein-Barr virus (EBV) plays an important role in the development of classical Hodgkin lymphoma (cHL) and its impact on clinical outcomes varies with different age groups. Elderly patients with EBV-positive cHL have worse outcomes, while younger adults may benefit moderately from EBV positivity or show no effect. The effects of EBV on children and adolescents with cHL are conflicting.

CANCERS (2022)

Add to Collection

Review Oncology

Signaling pathways of EBV-induced oncogenesis

Yin Luo, Yitong Liu, Chengkun Wang, Runliang Gan

Summary: Epstein-Barr virus is closely associated with multiple human cancers, mainly lymphomas and carcinomas. The virus can induce oncogenesis through activating various signaling pathways in host cells.

CANCER CELL INTERNATIONAL (2021)

Add to Collection

Article Immunology

Case Report: Non-negligible Epstein-Barr virus-associated posttransplant lymphoproliferative disorders in a lung transplant recipient

Juan Hu, Yong-Wei Yu, Dong-Sheng Han, Xue-Jie Li, Yi-Qi Zhang, Hong-Liu Cai, Yong-Hong Xiao, Xia Zheng

Summary: This study describes a lung transplant recipient who developed EBV-associated PTLD, highlighting the importance of monitoring EBV-DNA load as a sensitive indicator for early diagnosis and treatment.

FRONTIERS IN IMMUNOLOGY (2023)

Add to Collection

Article Multidisciplinary Sciences

Reappraisal of the prognostic value of Epstein-Barr virus status in monomorphic post-transplantation lymphoproliferative disorders-diffuse large B-cell lymphoma

Jwa Hoon Kim, Hyungwoo Cho, Heungsup Sung, Ah Ra Jung, Yoon Sei Lee, Sang-wook Lee, Jin-Sook Ryu, Eun Jin Chae, Kyoung Won Kim, Jooryung Huh, Chan-Sik Park, Dok Hyun Yoon, Cheolwon Suh

Summary: This study suggests that positive plasma EBV DNA is a stronger predictor for survival prognosis in patients with PTLD-DLBCL after transplantation compared to EBER or WB EBV DNA positivity, indicating its significant unfavorable impact on progression-free survival and overall survival.

SCIENTIFIC REPORTS (2021)

Add to Collection

Review Hematology

Circulating tumour DNA in B-cell lymphomas: current state and future prospects

Rahul Lakhotia, Mark Roschewski

Summary: Circulating tumor DNA (ctDNA) is a versatile analyte and emerging biomarker for lymphoid malignancies, providing a minimally invasive method to monitor treatment effectiveness and correlate with clinical outcomes in B-cell lymphomas. Standardization of analytical techniques and prospective validation within clinical studies are necessary for ctDNA to reach its full potential as a decision-making tool in oncology.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

Add to Collection

Article Oncology

Survival after autologous versus allogeneic transplantation in patients with relapsed and refractory Hodgkin lymphoma

Bita Fakhri, Elif Yilmaz, Feng Gao, Richard F. Ambinder, Richard Jones, Nancy L. Bartlett, Amanda Cashen, Nina Wagner-Johnston

Summary: For relapsed Hodgkin lymphoma, salvage chemotherapy followed by auto-HCT is the standard of care. It is important to identify subpopulations who could benefit from allo-HCT. The choice of transplant (auto-HCT or allo-HCT) did not affect PFS or OS after controlling for risk factors, but in patients with >= 3 high risk features, those who underwent allo-HCT had a slightly better 4-year PFS compared to the auto-HCT cohort.

LEUKEMIA & LYMPHOMA (2021)

Add to Collection

Article Hematology

Next-generation sequencing-based monitoring of circulating tumor DNA reveals clonotypic heterogeneity in untreated PTCL

Milos D. Miljkovic, Christopher Melani, Stefania Pittaluga, Rahul Lakhotia, Nicole Lucas, Allison Jacob, Erik Yusko, Elaine S. Jaffe, Wyndham H. Wilson, Mark Roschewski

Summary: Peripheral T-cell lymphomas (PTCLs) exhibit significant heterogeneity in terms of biology and clinical presentation, making treatment decisions challenging. This study showed that monitoring T-cell receptor (TCR) sequences using next-generation sequencing (NGS) identified tumor-specific clonotypes in PTCL patients undergoing frontline treatment. Patients with detectable ctDNA after therapy tended to have worse survival outcomes, indicating the potential utility of ctDNA as a prognostic marker in PTCL.

BLOOD ADVANCES (2021)

Add to Collection

Meeting Abstract Hematology

Phase 1b/2 Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory and Untreated Mantle Cell Lymphoma: Safety, Efficacy, and Molecular Analysis

Christopher Melani, Rahul Lakhotia, Stefania Pittaluga, Milos D. Miljkovic, James D. Phelan, Jagan R. Muppidi, Craig J. Thomas, Michele Ceribelli, Anna Marie Juanitez, Amynah Pradhan, Amy Hillsman, Seth M. Steinberg, Elaine S. Jaffe, Mark Roschewski, Louis M. Staudt, Wyndham H. Wilson

BLOOD (2021)

Add to Collection

Meeting Abstract Hematology

Phase 2 Study of Acalabrutinib Window Prior to Frontline Therapy in Untreated Aggressive B-Cell Lymphoma: Preliminary Results and Correlatives of Response to Acalabrutinib

Mark Roschewski, James D. Phelan, Stefania Pittaluga, Christopher Melani, Rahul Lakhotia, Jacob J. Chabon, Jagan R. Muppidi, Kathryn A. Lurain, Jillian Simard, Amynah Pradhan, Amy Hillsman, Madeline Rilko, Seth M. Steinberg, George W. Wright, Da Wei Huang, Yandan Yang, Michail S. Lionakis, Alexander Bagaev, Ekaterina Postovalova, Mark Meerson, Olga Kudryashova, Nikita Kotlov, Nathan H. Fowler, David M. Kurtz, Ash A. Alizadeh, Elaine S. Jaffe, Louis M. Staudt, Wyndham H. Wilson

BLOOD (2021)

Add to Collection

Article Hematology

Circulating tumor DNA predicts therapeutic outcome in mantle cell lymphoma

Rahul Lakhotia, Christopher Melani, Kieron Dunleavy, Stefania Pittaluga, Nakhle Saba, Liza Lindenberg, Esther Mena, Ethan Bergvall, Andrea Nicole Lucas, Allison Jacob, Erik Yusko, Seth M. Steinberg, Elaine S. Jaffe, Adrian Wiestner, Wyndham H. Wilson, Mark Roschewski

Summary: This study analyzed the dynamics of circulating tumor DNA (ctDNA) in patients with mantle cell lymphoma (MCL) following induction therapy. The results showed that patients with negative ctDNA after induction had longer survival, suggesting the potential of ctDNA as a prognostic biomarker. This supports further investigation into the use of ctDNA for response-adapted strategies in MCL.

BLOOD ADVANCES (2022)

Add to Collection

Letter Oncology

Is Dose-Adjusted EPOCH-R Less Effective in Children Than Adults With Primary Mediastinal B-Cell Lymphoma?

Rahul Lakhotia, Christopher Melani, Mark Roschewski, Wyndham H. Wilson

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Meeting Abstract Hematology

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed and Refractory Follicular Lymphoma: Analysis of Safety, Efficacy, and Minimal Residual Disease

Christopher Melani, Rahul Lakhotia, Stefania Pittaluga, James D. Phelan, Jillian Simard, Jagan R. Muppidi, Craig J. Thomas, Michele Ceribelli, Frances Anne Tosto, Rafic J. Farah, Seung Tae Lee, Amynah Pradhan, Anna Marie Juanitez, Seth M. Steinberg, Elaine S. Jaffe, Mark Roschewski, Louis M. Staudt, Wyndham H. Wilson

BLOOD (2022)

Add to Collection

Meeting Abstract Hematology

Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide in Combination with Polatuzumab (ViPOR-P) in Relapsed/Refractory B-Cell Lymphoma: Preliminary Analysis of Safety and Efficacy

Christopher Melani, Rahul Lakhotia, Stefania Pittaluga, James D. Phelan, Jillian Simard, Jagan R. Muppidi, Craig J. Thomas, Michele Ceribelli, Frances Anne Tosto, Amynah Pradhan, Anna Marie Juanitez, Seth M. Steinberg, Elaine S. Jaffe, Mark Roschewski, Louis M. Staudt, Wyndham H. Wilson

BLOOD (2022)

Add to Collection

Meeting Abstract Hematology

Effect of Isavuconazole on Plasma and CSF Levels of Ibrutinib and Plasma Levels of Liposomal Doxorubicin Among Patients Receiving Teddi-R for CNS Lymphoma

Jillian Simard, Cody Peer, Rahul Lakhotia, Christopher Melani, Amynah Pradhan, Andrea Nicole Lucas, William D. Figg, Wyndham H. Wilson, Mark Roschewski

BLOOD (2022)

Add to Collection

Article Hematology

Prognostic factors for adult patients with Burkitt lymphoma treated with dose-adjusted EPOCH-R

Rahul Lakhotia, Kieron Dunleavy, Jeremy S. Abramson, Brian K. Link, Bayard L. Powell, Christopher Melani, Andrea N. Lucas, Seth M. Steinberg, Jonathan W. Friedberg, Brad S. Kahl, Richard F. Little, Nancy L. Bartlett, Ariela Noy, Wyndham H. Wilson, Mark Roschewski

BLOOD ADVANCES (2023)

Add to Collection

Meeting Abstract Oncology

Phase 2 Response-Adapted Study of Ibrutinib With Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, Rituximab (TEDDI-R) for Secondary CNS Lymphoma

Jillian Simard, James D. Phelan, Christopher Melani, Rahul Lakhotia, Stefania Pittaluga, Jagan R. Muppidi, Michail S. Lionakis, Cody Peer, Amynah Pradhan, Matthias Holdhoff, Lode J. Swinnen, Kieron Dunleavy, Catherine Lai, Sami Ibrahimi, Michael Glantz, John A. Butman, Kim Johnson, Seth M. Steinberg, William D. Figg, Elaine S. Jaffe, Louis M. Staudt, Wyndham H. Wilson, Mark Roschewski

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2023)

Add to Collection

Meeting Abstract Oncology

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory (R/R) and Treatment-Naive (TN) Mantle Cell Lymphoma (MCL)

Rahul Lakhotia, Stefania Pittaluga, James Phelan, Yandan Yang, Theresa Davies-Hill, Jillian Simard, Jagan Muppidi, Da Wei Huang, Craig Thomas, Michele Ceribelli, Frances Tosto, Amynah Pradhan, Anna Juanitez, Lisa Rimsza, Allison Jacob, Heidi Simmons, Seth Steinberg, Elaine Jaffe, Louis Staudt, Mark Roschewski, Wyndham Wilson, Christopher Melani

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2023)

Add to Collection

Meeting Abstract Oncology

Phase 2 Study of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders (LPD) and EBV-Positive Non-Hodgkin Lymphomas (NHL)

Disha Dalela, Rahul Lakhotia, Stefania Pittaluga, Jagan Muppidi, Seth Steinberg, James Phelan, Sarah Evans, Amynah Pradhan, Elaine Jaffe, Wyndham Wilson, Mark Roschewski, Christopher Melani

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2023)

Add to Collection

Review Oncology

A Review on Splenic Diffuse Red Pulp Small B-Cell Lymphoma

Elif Yilmaz, Arashpreet Chhina, Victor E. Nava, Anita Aggarwal

Summary: Splenic diffuse red pulp small B-cell lymphoma (SDRPL) is a rare disease, difficult to diagnose without splenic tissue examination. It has distinct immunophenotypic features that differentiate it from other types of lymphomas, with no standard treatment regimen established yet, suggesting a need for further research into effective therapeutic approaches.

CURRENT ONCOLOGY (2021)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.